Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

This study has been terminated.
(The Clinical Development Program for MGCD0103 is being re-evaluated)
Information provided by (Responsible Party):
Mirati Therapeutics Inc. Identifier:
First received: September 7, 2006
Last updated: June 4, 2015
Last verified: June 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2008
  Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: June 4, 2015